Sciencealert has reported that GlaxoSmithKline says it will no longer file patents for its medicines in the world’s 50 Least Developed Countries (LDCs) and Low Income Countries (LICs), which means that when it brings out a new HIV or cancer drug in places like Afghanistan, Rwanda, or Cambodia, it won’t prevent other manufacturers from supplying generic, more affordable versions of the same medication to help make medicine more accessible to the world’s poorest people.

Read the full story HERE